Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 7/20 | 0.80 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762333 | 0.89 | ENPP1 (1.00) | ENPP1MAP2K1EGFRERBB2SRC | |
| SCHEMBL30117274 | 0.89 | ENPP1 (1.00) | ENPP1MAP2K1EGFRERBB2SRC | |
| SCHEMBL23726976 | 0.87 | ENPP1 (0.66) | ENPP1MAP2K1EGFRERBB2SRC | |
| SCHEMBL23742851 | 0.86 | ENPP1 (0.70) | ENPP1MAP2K1EGFRERBB2SRC | |
| SCHEMBL29055116 | 0.85 | ENPP1 (0.71) | ENPP1MAP2K1EGFRERBB2PRKDC | |
| SCHEMBL30080222 | 0.85 | ENPP1 (0.71) | ENPP1MAP2K1EGFRERBB2SRC | |
| SCHEMBL25225113 | 0.81 | ENPP1 (0.74) | ENPP1EGFR | |
| SCHEMBL25656207 | 0.80 | ENPP1 (0.82) | ENPP1 | |
| SCHEMBL30117269 | 0.80 | ENPP1 (0.79) | ENPP1MAP2K1EGFRERBB2SRC | |
| SCHEMBL23762334 | 0.80 | ENPP1 (0.79) | ENPP1MAP2K1EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4100394-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115362145-A | Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20210253556-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. | 2021-08-19 | — | — | US | disclosed |
| WO-2021158829-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885MAP2K1 2856/4885EGFR 3428/4885 |
| US-11591313-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | ENPP1 1/4885MAP2K1 2856/4885EGFR 3428/4885 |
| US-20210253556-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885MAP2K1 2856/4885EGFR 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.